Use of hypoxia-activated prodrugs has emerged as a strategy for selectively targeting tumors in hypoxic conditions harboring reductive environments. In this issue of Cell Chemical Biology, Skwarska et al. (2021) report a hypoxia-activated prodrug targeting histone deacetylases (lysine deacetylases, KDACs) selectively over normoxic cells with activity in an animal model.

中文翻译：

---

缺氧激活的 KDAC 抑制剂：从非靶向治疗中喘口气

使用缺氧激活的前药已成为一种在具有还原环境的缺氧条件下选择性靶向肿瘤的策略。在本期《细胞化学生物学》中，Skwarska 等人。(2021) 报告了一种缺氧激活的前药，其靶向组蛋白脱乙酰酶（赖氨酸脱乙酰酶，KDAC）在动物模型中选择性地超过常氧细胞具有活性。